Kennedy Andrew S, Nutting Charles, Coldwell Douglas, Gaiser James, Drachenberg Cinthia
Wake Radiology Oncology, Cary, NC 27511, USA.
Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63. doi: 10.1016/j.ijrobp.2004.09.004.
Radioactive microsphere (90)Y therapy is increasingly used for primary and metastatic solid tumors in the liver. We present an analysis of 4 explanted livers previously treated with (90)Y microsphere agents (glass or resin). One tumor nodule was analyzed with submillimeter three-dimensional microdosimetry.
Four patients received hepatic artery delivery of (90)Y microspheres for unresectable hepatocellular and colon cancers. Whole livers were explanted as part of lifesaving cadaveric transplant in 2 patients with hepatoma. These patients had received glass microspheres as a procedural bridge to transplant. Autopsy was performed on 2 patients with colon cancer who died of progressive metastatic disease and who had been treated with resin microspheres. Complete pathologic review was performed on each whole liver, including estimation of the response of the tumor to therapy, distribution of microspheres in the tumor and normal liver tissues, and normal-tissue radiation response. A biopsy taken from the edge of a tumor nodule was sectioned serially for three-dimensional radiation dosimetry analyses. Three-dimensional microsphere coordinates within the biopsy specimen were used to calculate dosage using a three-dimensional dose kernel. Isodose coverage of tumor and normal liver areas and total dose delivered were determined.
Preferential and heterogeneous deposition of microspheres was noted at the edge of tumor nodules compared with the center portion of the tumor or normal liver parenchyma. Both glass and resin microspheres delivered high cumulative doses to the tumor, which varied from 100 Gy to more than 3000 Gy. No veno-occlusive disease or widespread radiation hepatitis was seen.
Microsphere ((90)Y) therapy delivers high numbers of spheres with resulting high total doses of radiation, preferentially in the periphery of tumors. Normal liver parenchyma showed little radiation effect away from the tumors. Heterogeneous high-dose regions in the tumor were produced by both glass and resin microspheres.
放射性微球(90)Y疗法越来越多地用于肝脏原发性和转移性实体瘤。我们对4例先前接受过(90)Y微球制剂(玻璃或树脂)治疗的离体肝脏进行了分析。对一个肿瘤结节进行了亚毫米级三维微剂量测定分析。
4例患者因无法切除的肝细胞癌和结肠癌接受了经肝动脉注入(90)Y微球治疗。2例肝癌患者作为挽救生命的尸体肝移植的一部分接受了全肝切除。这些患者接受玻璃微球作为移植的过渡治疗。对2例死于进行性转移性疾病且接受过树脂微球治疗的结肠癌患者进行了尸检。对每个全肝进行了完整的病理检查,包括评估肿瘤对治疗的反应、微球在肿瘤和正常肝组织中的分布以及正常组织的辐射反应。从肿瘤结节边缘取活检组织进行连续切片以进行三维辐射剂量分析。活检标本内的三维微球坐标用于使用三维剂量核计算剂量。确定肿瘤和正常肝区域的等剂量覆盖范围以及所输送的总剂量。
与肿瘤中心部分或正常肝实质相比,在肿瘤结节边缘观察到微球的优先和异质性沉积。玻璃微球和树脂微球均向肿瘤输送了高累积剂量,范围从100 Gy到超过3000 Gy。未观察到静脉闭塞性疾病或广泛的放射性肝炎。
微球((90)Y)疗法输送大量微球,从而产生高总辐射剂量,优先集中在肿瘤周边。远离肿瘤的正常肝实质几乎没有辐射效应。玻璃微球和树脂微球均在肿瘤内产生了异质性高剂量区域。